NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PANACEABIO · data 2026-10-30
Panacea Biotec Limited
In plain words
Price: 51.6% below its 52-week high of ₹647.
Delivery: 52.8% of traded shares were kept for delivery over the last 10 sessions, against 52.5% over the last 60.
Latest results: a net profit of ₹2 cr for the quarter ended Jun 2026 (-43.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹673 cr |
| Net profit (last 12 months) | ₹-7 cr |
| Sales growth, 3 years (yearly) | 10.1% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q1 FY27)
PANACEABIO Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹199.57 crore, up 19.7% YoY and up 19.7% QoQ.
Net profit was ₹2.3 crore, down 43.2% YoY and up 342.3% QoQ.
Operating margin was 2.8% (0.7% a year ago).
EPS was ₹0.38, down 42.4% YoY and up 375% QoQ.
PANACEABIO के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹199.57 करोड़; पिछले साल की तुलना में 19.7% की बढ़त, पिछली तिमाही की तुलना में 19.7% की बढ़त।
शुद्ध मुनाफ़ा: ₹2.3 करोड़; पिछले साल की तुलना में 43.2% की गिरावट, पिछली तिमाही की तुलना में 342.3% की बढ़त।
ऑपरेटिंग मार्जिन: 2.8% (एक साल पहले 0.7%)।
EPS: ₹0.38; पिछले साल की तुलना में 42.4% की गिरावट, पिछली तिमाही की तुलना में 375% की बढ़त।
PANACEABIOના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹199.57 કરોડ; ગયા વર્ષની સરખામણીએ 19.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 19.7% વધારો.
ચોખ્ખો નફો: ₹2.3 કરોડ; ગયા વર્ષની સરખામણીએ 43.2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 342.3% વધારો.
ઓપરેટિંગ માર્જિન: 2.8% (એક વર્ષ પહેલાં 0.7%).
EPS: ₹0.38; ગયા વર્ષની સરખામણીએ 42.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 375% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 52.4% over the last 20 sessions vs 50.6% in the 40 before (1.04x); shares delivered per day 0.49x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 13 Aug 26Results Q1 FY27 results: profit −43.2% YoY -0.9% next session
- 31 May 26Results Q4 FY26 results: turned to profit vs a year ago -3.6% next session
- 11 Feb 26Results Q3 FY26 results: profit −11.9% YoY -4.6% next session
- 14 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -3.6% next session
- 14 Aug 25Results Q1 FY26 results: turned to profit vs a year ago -5.2% next session
- 30 May 25Results Q4 FY25 results: loss widened vs a year ago -3.3% next session
- 14 Feb 25Results Q3 FY25 results: turned to profit vs a year ago -0.1% next session
- 14 Nov 24Results Q2 FY25 results: turned to profit vs a year ago +10.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹200 cr | ₹2 cr | -43.2% | 2.8% | 0.38 |
| Mar 2026 | ₹167 cr | ₹1 cr | — | 1.5% | 0.08 |
| Dec 2025 | ₹165 cr | ₹4 cr | -11.9% | 7.1% | 0.65 |
| Sept 2025 | ₹141 cr | ₹-14 cr | -390.0% | -12.6% | -2.27 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 72.48% | 72.48% | 72.48% | 72.48% |
| Foreign institutions (FII) | 2.75% | 2.31% | 1.60% | 1.36% |
| Domestic institutions (DII) | 2.47% | 2.25% | 1.97% | 1.85% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 14.77% | 14.62% | 15.90% | 16.59% |
| Number of shareholders | 32,961 | 33,532 | 32,620 | 34,597 |
Common questions
What was Panacea Biotec Limited's latest quarterly profit?
Panacea Biotec Limited reported a net profit of ₹2 cr for the quarter ended Jun 2026 (-43.2% on the same quarter a year earlier), on revenue of ₹200 cr.
How much do promoters hold in Panacea Biotec Limited?
Promoters held 72.48% of Panacea Biotec Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Panacea Biotec Limited debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is the 52-week high and low of Panacea Biotec Limited?
The 52-week high is ₹647 and the 52-week low is ₹292.4.
Similar companies
Sakar Healthcare Ltd (SAKAR) · Beta Drugs Ltd. (BETA) · Hester Biosciences Limited (HESTERBIO) · Indoco Remedies Limited (INDOCO) · Syncom Formulation (India) Ltd. (SYNCOMF)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PANACEABIO in NSE Scanner →